Open Innovation Portal





DNDi is dedicated to fostering innovation and advancement in global health by supporting the neglected diseases research community to develop safe, effective, and affordable new treatments for neglected patients.

Open innovation at DNDi continues to grow and expand, now ranging from work with university chemistry teaching labs to support drug discovery, through to a virtual Open Pharma community to support lead optimization of chemical compounds that could one day become new medicines.

In keeping with our Intellectual Property Policy, we disseminate the scientific knowledge gained through research projects with our many partners. Data are shared through scientific articles, and in the public domain on WIPO Re:Search and the ChEMBL medicinal chemistry database.  




logo MycetOS project

The Mycetoma Open Source project (MycetOS) uses an Open Pharma approach to discover new treatments (new chemical entities, or NCEs) for fungal mycetoma (eumycetoma).

Open Synthesis Network (OSN)

The Open Synthesis Network is a collaborative project that aims to engage master’s and undergraduate students in research for neglected diseases.

Guides to free computational chemistry tools for drug discovery

AMG Consultants has produced guides to share free solutions to common problems faced by medicinal and computational chemists in not-for-profit research.

NTD Drug Discovery Booster

Drug Discovery Booster

The NTD Drug Discovery Booster aims to speed up the process and cut the cost of finding new treatments for leishmaniasis and Chagas disease. The project brings together DNDi and seven pharmaceutical companies: Abbvie, AstraZeneca plc, Celgene Corporation, Eisai Co Ltd, Merck, Shionogi & Co Ltd, and Takeda Pharmaceutical Ltd.




Successful screening collaboration leads to a new lead optimization project

DNDi identified an interesting new hit compound active against Leishmania donovani from an innovative screening collaboration with Pfizer.

The Pathogen Box

The Pathogen Box contains ~400 diverse, drug-like molecules active against neglected diseases of interest and is available free of charge.

Development and validation of a novel Leishmania screening cascade

This new screening cascade was used to screen a compound collection named the Diversity Oriented Synthesis (DOS) Informer Set (9,907 compounds) and led to the identification of two new chemical series with antileishmanial activity.

Antiprotozoal activity profiling of approved drugs: a starting point toward drug repositioning

A set of 100 registered drugs with drug repositioning potential for neglected tropical diseases was assembled. The compound collection was systematically screened against protozoan parasites, T. b. rhodesiense, L. donovani, T. cruzi and P. falciparum.

Source data from neglected disease R&D pipeline review

In late 2013, DNDi and colleagues published an analysis in The Lancet Global Health looking at the R&D landscape over the last decade in terms of new therapeutic products for 49 so-called neglected diseases. In the hope of promoting further research, we have created a public data-sharing page with full datasets from the study freely accessible to all.

DNDi Screening of the MMV Open Access Malaria Box for HAT, VL, and Chagas disease

Screening of the MMV Open Access Malaria Box in the search for new drugs against Human African Trypanosomiasis (HAT), visceral leishmaniasis and Chagas disease.

iNTRODB – an Integrated system for searching drug-target proteins from parasitic protozoa genomes

iNTRODB is an integrated system for searching drug-target proteins from parasitic protozoa genomes that cause neglected tropical diseases, including leishmaniasis, Chagas’ disease and human African trypanosomiasis.

Screening and lead optimization of new compounds for Chagas disease (>300,000 compounds)

We have evaluated multiple hits generated from a high-throughput screen of over 300,000 compounds to identify inhibitors of T. cruzi. These studies have resulted in the discovery of two novel series currently in lead optimisation.

Two series of fenarimols for the treatment of Chagas disease

This second release includes data on a further 84 compounds from the two more advanced series of fenarimols which include the preclinical candidates EPL-BS0967 and EPL-BS1246, both of which are T.cruzi CYP51 inhibitors.

Screening identifies new compounds for HAT

Identification of compounds against Trypanosoma brucei brucei BS427 by high-throughput screening of whole parasites (87,926 compounds).

SCYNEXIS Inc. as part of the DNDi HAT Lead Optimization Consortium 

Screening and optimization of specific chemical series against Human African Trypanosomiasis (HAT): 4926 compounds.


For more information: